261 Endometrial Cancer Clinical Trials Recruiting Now (July 2026): MMR Status, Dostarlimab, T-DXd, Selinexor, RAINBO Molecular Classification, MDM2 Navtemadlin
Last updated: July 1, 2026
Answer a few questions to find clinical trials matched to your specific Endometrial Cancer situation.
Usually 2–3 minutes. No sign-up.
Find matching trials →
Current Clinical Trial Landscape
Active research areas in 2026:
- IO + chemo as new standard first-line: pembrolizumab (NRG-GY018) and dostarlimab (RUBY) both practice-changing
- ADCs: trastuzumab deruxtecan (T-DXd) for HER2+, sacituzumab tirumotecan, puxitatug samrotecan (B7-H4)
- Lenvatinib + pembrolizumab for pMMR/MSS disease (KEYNOTE-775)
- Molecular classification-guided treatment (POLE, dMMR, p53, NSMP subtypes)
- Fertility-sparing approaches for early-stage endometrioid carcinoma
Standard of care: First-line advanced: carboplatin/paclitaxel + pembrolizumab or dostarlimab (regardless of MMR status). Second-line dMMR: pembrolizumab or dostarlimab monotherapy. Second-line pMMR: lenvatinib + pembrolizumab. MMR/MSI status and p53 mutation are key biomarkers.
Recruiting Trials by Treatment Setting
Adjuvant — Molecular-Classification-Guided
The biggest adjuvant story in endometrial cancer is treatment-tailoring by molecular classification (TCGA-style 4-group profiling: p53abn / MMRd / NSMP / POLEmut):
- NCT05255653 - RAINBO (Leiden University): umbrella Phase 2/3 program assigning patients to one of four sub-trials based on tumor molecular profile: p53abn-RED, MMRd-GREEN, NSMP-ORANGE, POLEmut-BLUE. Landmark adjuvant trial for molecular-classification-guided EC treatment.
- NCT06712472 - RAINBO-RED: maintenance olaparib vs observation in p53abn EC after adjuvant treatment (Phase 3, Gustave Roussy — connected to the broader RAINBO umbrella).
Advanced / Recurrent — First-Line
IO + chemo is standard. Trials test ADC additions and novel combinations:
- ADC combinations (cross-class hubs: HER2 ADCs · TROP2 ADCs):
- NCT06952504 - TroFuse-033: sacituzumab tirumotecan (TROP2 ADC) + pembrolizumab vs placebo + pembrolizumab (Phase 3, Merck)
- NCT06989112 - DESTINY-Endometrial01: T-DXd + rilvegostomig for HER2+ endometrial cancer (Phase 3, AstraZeneca)
- NCT07044336 - Puxitatug samrotecan (AZD8205, B7-H4 ADC) vs chemo in B7-H4-selected endometrial cancer (Phase 3, AstraZeneca)
- Novel IO combinations:
- NCT06340568 - Fern-EC-01: investigational therapy vs chemo in advanced endometrial cancer (Phase 3, BioNTech)
- NCT06584032 - Fruquintinib + sintilimab for advanced endometrial cancer (Phase 3, HUTCHMED)
Advanced / Recurrent — Second-Line and Beyond
After first-line IO+chemo failure, HER2-targeted, ADC, and novel agents:
- HER2-targeted:
- NCT05256225 - Trastuzumab/pertuzumab added to chemo for HER2+ uterine cancers (Phase 3, NCI)
- NCT07022483 - T-DXd vs standard chemo for HER2-expressing endometrial cancer (Phase 3, Daiichi Sankyo)
- Novel agents:
- NCT07166094 - RAINFOL-03: Rina-S (rinatabart sesutecan, FRα ADC) vs investigator's choice in recurrent endometrial cancer (Phase 3, Genmab)
- NCT07198074 - Bevacizumab + carboplatin/paclitaxel for recurrent endometrial cancer (Phase 3, NCI)
- Maintenance (TP53-stratified):
- NCT05611931 - XPORT-EC-042: selinexor maintenance for p53 wild-type endometrial cancer (Phase 3, Karyopharm)
- NCT05797831 - Navtemadlin (MDM2 antagonist) as maintenance in TP53WT advanced or recurrent endometrial cancer who responded to chemotherapy (Phase 2/3, Kartos). Another TP53WT-targeted maintenance approach distinct from selinexor's XPO1 mechanism.
Fertility-Sparing Treatment
For young women with early-stage endometrioid carcinoma who want to preserve fertility:
-
- NCT07319429 - FEMUS: refining fertility-sparing treatment based on molecular classification (Phase 2/3, Fudan University)
- NCT06379113 - GnRHa + letrozole in obese progestin-insensitive endometrial cancer (Phase 3)
- NCT05316935 - GnRHa + letrozole in non-obese progestin-insensitive endometrial cancer (Phase 3)
- NCT05316467 - Weight management + megestrol acetate in early-stage endometrioid carcinoma (Phase 3)
Showing selected notable trials. View all 261 recruiting interventional trials on ClinicalTrials.gov.
Frequently Asked Questions
How do I find endometrial cancer clinical trials I'm eligible for?
Enter your endometrial cancer details into ClinTrialFinder — including MMR/MSI status (dMMR vs pMMR), p53 mutation, HER2 status, and prior treatments. The AI matches you with trials based on your specific profile in minutes.
What endometrial cancer trials are currently recruiting?
There are 261 recruiting interventional trials for endometrial cancer in July 2026 including 26 Phase 3 studies. Recent Phase 3: ARTIST adding bevacizumab to carbo/paclitaxel NCT07198074, Puxitatug Samrotecan AZD8205 (B7-H4 ADC) Bluestar-Endo NCT07044336, Phesgo/Herceptin Hylecta HER2+ endometrial NCT05256225, MK-2870 + pembro vs pembro NCT06952504, Rina-S NCT07166094. Active classes: checkpoint immunotherapy combinations (pembrolizumab, dostarlimab), ADCs (T-DXd, sacituzumab tirumotecan, Puxitatug Samrotecan B7-H4, Rina-S folate receptor — see HER2 ADCs hub), lenvatinib combinations, MMR/MSI-based stratification (RAINBO molecular classification), MDM2 navtemadlin, selinexor, and fertility-sparing approaches.
Find Endometrial Cancer Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.
Find Matching Trials
